First human tests begin for promising eczema injection

NCT ID NCT06055361

Recruiting now Disease control Sponsor: Brexogen Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new injectable medication called BxC-I17e for people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and well-tolerated when given as single or multiple shots under the skin. Researchers will also look for early signs that it might help reduce eczema symptoms and improve quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arkansas Research Trials
RECRUITING

North Little Rock, Arkansas, 72117, United States

Contact
DermDox Centers for Dermatology
RECRUITING

Camp Hill, Pennsylvania, 17011, United States

Contact
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS